Kavenpreet Singh Bal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Kavenpreet Singh Bal has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
A.R. Gomez-Lara
1 shared publicationAaron Krug
Huntington Hospital, Pasadena, CA, USA
1 shared publicationAlka M. Kanaya
Department of Medicine, University of California, San Francisco, California, USA
1 shared publicationAnandita Kulkarni
Baylor Scott & White Health, The Heart Hospital, Plano, Texas, USA
1 shared publication- Andrea M. Yeung
Diabetes Technology Society, Burlingame, CA, USA
1 shared publication B.G. Teshome
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11) , 103329
Lipoprotein(a) in Disaggregated South Asian Groups
- 13 October 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11) , 103329
Open AccessLipoprotein(a) in Disaggregated South Asian Groups
- 18 October 2025
- Published by Elsevier in Annals of Epidemiology
- Vol. 109, 163
A quality improvement study of gain-framed and loss-framed medication reminder emails to improve statin medication adherence
- 18 October 2025
- Published by Elsevier in Annals of Epidemiology
- Vol. 109, 163
A quality improvement study of gain-framed and loss-framed medication reminder emails to improve statin medication adherence
- Open Access
- 14 March 2025
- Published by The Permanente Federation in The Permanente Journal
- Vol. 29 (1) , 43-49
Impact of the Advent of Collagenase Clostridium histolyticum on the Surgical Management of Peyronie’s Disease: A Population-Based Analysis
Peyronie's disease (PD) is a progressive fibrotic disorder of the penis that can induce pain and erectile dysfunction and has various treatment modalities, including surgical, pharmaceutical, and Clostridium histolyticum injection therapies. The authors used electronic medical records from Kaiser Permanente Southern California, an integrated health care system that consists of 15 medical centers, and identified patients diagnosed with stable PD without concomitant erectile dysfunction from January 1, 2004, to December 31, 2020. Baseline characteristics between surgical and injection groups were compared using Chi-squared and Kruskal-Wallis tests. Multivariable logistic regression with adjustment of confounders was implemented to identify which variables may influence whether patients received injection or surgical therapy. A total of 11,706 patients with PD were identified. The rate of new PD diagnosis per 100,000 patients increased by 0.37 every year, P < .05. The incident rate (per 1000 eligible patients) of surgical management declined on average by 0.40 each year (P < .001), although there was an increase rate of 1.19 for injection therapy (P < .001). On multivariable modeling, patients 45-54 years of age were more likely to receive injection therapy as the primary treatment for PD (adjusted odds ratio = 2.77; P = .002; confidence interval = 1.34-5.73). This study illustrates that pentoxifylline is now more frequently used than colchicine and vitamin E as oral treatments for PD, while collagenase C. histolyticum injection therapy is now more prevalently employed than surgical intervention as the therapeutic approach for PD.
- 14 March 2025
- Published by The Permanente Federation in The Permanente Journal
- Vol. 29 (1) , 43-49
Open AccessImpact of the Advent of Collagenase Clostridium histolyticum on the Surgical Management of Peyronie’s Disease: A Population-Based Analysis
Peyronie's disease (PD) is a progressive fibrotic disorder of the penis that can induce pain and erectile dysfunction and has various treatment modalities, including surgical, pharmaceutical, and Clostridium histolyticum injection therapies. The authors used electronic medical records from Kaiser Permanente Southern California, an integrated health care system that consists of 15 medical centers, and identified patients diagnosed with stable PD without concomitant erectile dysfunction from January 1, 2004, to December 31, 2020. Baseline characteristics between surgical and injection groups were compared using Chi-squared and Kruskal-Wallis tests. Multivariable logistic regression with adjustment of confounders was implemented to identify which variables may influence whether patients received injection or surgical therapy. A total of 11,706 patients with PD were identified. The rate of new PD diagnosis per 100,000 patients increased by 0.37 every year, P < .05. The incident rate (per 1000 eligible patients) of surgical management declined on average by 0.40 each year (P < .001), although there was an increase rate of 1.19 for injection therapy (P < .001). On multivariable modeling, patients 45-54 years of age were more likely to receive injection therapy as the primary treatment for PD (adjusted odds ratio = 2.77; P = .002; confidence interval = 1.34-5.73). This study illustrates that pentoxifylline is now more frequently used than colchicine and vitamin E as oral treatments for PD, while collagenase C. histolyticum injection therapy is now more prevalently employed than surgical intervention as the therapeutic approach for PD.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 6886806
Pilot Study of Early Adoption of Automated Insulin Delivery in Underresourced Youth
Background: Disparities in outcomes and technology use in children with Type 1 diabetes (T1D) from underresourced backgrounds are well documented. The feasibility of initiating automated insulin delivery (AID) soon after diagnosis of T1D is less certain in this population. This pilot study assessed the feasibility and acceptability of providing access to the Tandem Control‐IQ AID system to children with public insurance soon after T1D diagnosis. Methods: Publicly insured children aged 6–21 years of age within 3 months of T1D diagnosis were eligible for the study. Participants were randomized 2:1 to AID or usual care for 6 months. Continuous glucose monitoring data were collected at baseline, 3 months, and 6 months. Caregivers and youth completed closing surveys and participated in focus group interviews to assess safety and user experience. Results: Nineteen youth were enrolled, with thirteen in the intervention and six in the control group. The mean age was 11.5 ± 2.3 years, 47% were female, and 89% were from underrepresented racial or ethnic groups. A larger proportion of the AID group compared to the control group achieved the American Diabetes Association benchmark of > 70% time in range (50% vs. 0% of participants at 3 months; 37% vs. 0% of participants at 6 months; not statistically significant). All caregivers and 69% of youth in the AID group reported satisfaction, and 85% of youth continued using AID 6 months after the completion of the study. Focus groups showed favorable experiences with AID use. Conclusion: Early initiation of AID is feasible and acceptable in youth with recently diagnosed T1D from underresourced populations who historically experience lower technology adoption and less optimal glycemic outcomes. Diabetes clinicians should consider providing tailored support and dedicated resources to families early in diagnosis with T1D to promote AID initiation and continued use.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 6886806
Open AccessPilot Study of Early Adoption of Automated Insulin Delivery in Underresourced Youth
Background: Disparities in outcomes and technology use in children with Type 1 diabetes (T1D) from underresourced backgrounds are well documented. The feasibility of initiating automated insulin delivery (AID) soon after diagnosis of T1D is less certain in this population. This pilot study assessed the feasibility and acceptability of providing access to the Tandem Control‐IQ AID system to children with public insurance soon after T1D diagnosis. Methods: Publicly insured children aged 6–21 years of age within 3 months of T1D diagnosis were eligible for the study. Participants were randomized 2:1 to AID or usual care for 6 months. Continuous glucose monitoring data were collected at baseline, 3 months, and 6 months. Caregivers and youth completed closing surveys and participated in focus group interviews to assess safety and user experience. Results: Nineteen youth were enrolled, with thirteen in the intervention and six in the control group. The mean age was 11.5 ± 2.3 years, 47% were female, and 89% were from underrepresented racial or ethnic groups. A larger proportion of the AID group compared to the control group achieved the American Diabetes Association benchmark of > 70% time in range (50% vs. 0% of participants at 3 months; 37% vs. 0% of participants at 6 months; not statistically significant). All caregivers and 69% of youth in the AID group reported satisfaction, and 85% of youth continued using AID 6 months after the completion of the study. Focus groups showed favorable experiences with AID use. Conclusion: Early initiation of AID is feasible and acceptable in youth with recently diagnosed T1D from underresourced populations who historically experience lower technology adoption and less optimal glycemic outcomes. Diabetes clinicians should consider providing tailored support and dedicated resources to families early in diagnosis with T1D to promote AID initiation and continued use.